pCMV14-3X-Flag-SARS-CoV-2 S Citations (23)
Originally described in: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PubMed Journal
Articles Citing pCMV14-3X-Flag-SARS-CoV-2 S
| Articles |
|---|
| Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol. Condor Capcha JM, Lambert G, Dykxhoorn DM, Salerno AG, Hare JM, Whitt MA, Pahwa S, Jayaweera DT, Shehadeh LA. Front Cardiovasc Med. 2021 Jan 15;7:618651. doi: 10.3389/fcvm.2020.618651. eCollection 2020. PubMed |
| Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. Beltran-Pavez C, Riquelme-Barrios S, Oyarzun-Arrau A, Gaete-Argel A, Gonzalez-Stegmaier R, Cereceda-Solis K, Aguirre A, Travisany D, Palma-Vejares R, Barriga GP, Gaggero A, Martinez-Valdebenito C, Corre NL, Ferres M, Balcells ME, Fernandez J, Ramirez E, Villarroel F, Valiente-Echeverria F, Soto-Rifo R. Sci Adv. 2021 Feb 12;7(7). pii: 7/7/eabe6855. doi: 10.1126/sciadv.abe6855. Print 2021 Feb. PubMed |
| A variant in TMPRSS2 is associated with decreased disease severity in COVID-19. Ravikanth V, Sasikala M, Naveen V, Latha SS, Parsa KVL, Vijayasarathy K, Amanchy R, Avanthi S, Govardhan B, Rakesh K, Kumari DS, Srikaran B, Rao GV, Reddy DN. Meta Gene. 2021 Sep;29:100930. doi: 10.1016/j.mgene.2021.100930. Epub 2021 May 28. PubMed |
| Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, Awasthi A, Surjit M. Front Immunol. 2021 May 24;12:641447. doi: 10.3389/fimmu.2021.641447. eCollection 2021. PubMed |
| Seroprevalence of SARS-CoV-2 antibodies among rural healthcare workers. Neises JZ, Hossain MS, Sultana R, Wanniarachchi KN, Wollman JW, Nelson E, Specker BL, Hoppe AD, Lawson SR, Thiex NW. J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27224. PubMed |
| Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19. Shin J, Toyoda S, Nishitani S, Fukuhara A, Kita S, Otsuki M, Shimomura I. Diabetes. 2021 Dec;70(12):2745-2755. doi: 10.2337/db20-1094. Epub 2021 Oct 6. PubMed |
| A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Hanke L, Das H, Sheward DJ, Perez Vidakovics L, Urgard E, Moliner-Morro A, Kim C, Karl V, Pankow A, Smith NL, Porebski B, Fernandez-Capetillo O, Sezgin E, Pedersen GK, Coquet JM, Hallberg BM, Murrell B, McInerney GM. Nat Commun. 2022 Jan 10;13(1):155. doi: 10.1038/s41467-021-27610-z. PubMed |
| A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Coria LM, Saposnik LM, Pueblas Castro C, Castro EF, Bruno LA, Stone WB, Perez PS, Darriba ML, Chemes LB, Alcain J, Mazzitelli I, Varese A, Salvatori M, Auguste AJ, Alvarez DE, Pasquevich KA, Cassataro J. Front Immunol. 2022 Feb 28;13:844837. doi: 10.3389/fimmu.2022.844837. eCollection 2022. PubMed |
| Serum extracellular vesicles profiling is associated with COVID-19 progression and immune responses. Yim KHW, Borgoni S, Chahwan R. J Extracell Biol. 2022 Apr;1(4):e37. doi: 10.1002/jex2.37. Epub 2022 Apr 20. PubMed |
| Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor. Fonnesu R, Thunuguntla VBSC, Veeramachaneni GK, Bondili JS, La Rocca V, Filipponi C, Spezia PG, Sidoti M, Plicanti E, Quaranta P, Freer G, Pistello M, Mathai ML, Lai M. Viruses. 2022 May 17;14(5). pii: v14051080. doi: 10.3390/v14051080. PubMed |
| Expression profiles of respiratory V-ATPase and calprotectin in SARS-CoV-2 infection. Hou Y, Wang T, Ding Y, Yu T, Cui Y, Nie H. Cell Death Discov. 2022 Aug 16;8(1):362. doi: 10.1038/s41420-022-01158-3. PubMed |
| SARS-CoV-2 pseudotyped virus persists on the surface of multiple produce but can be inactivated with gaseous ozone. Mortazavi M, Bains A, Afsah-Hejri L, Ehsani R, LiWang PJ. Heliyon. 2022 Aug;8(8):e10280. doi: 10.1016/j.heliyon.2022.e10280. Epub 2022 Aug 15. PubMed |
| An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension. Fuchs E, Rudnik-Jansen I, Dinesen A, Selnihhin D, Mandrup OA, Thiam K, Kjems J, Pedersen FS, Howard KA. Acta Biomater. 2022 Nov;153:411-418. doi: 10.1016/j.actbio.2022.09.048. Epub 2022 Sep 24. PubMed |
| SARS-CoV-2 down-regulates ACE2 through lysosomal degradation. Lu Y, Zhu Q, Fox DM, Gao C, Stanley SA, Luo K. Mol Biol Cell. 2022 Dec 1;33(14):ar147. doi: 10.1091/mbc.E22-02-0045. Epub 2022 Oct 26. PubMed |
| Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression. Bhullar KS, Nael MA, Elokely KM, Drews SJ, Wu J. Pharmaceutics. 2022 Sep 26;14(10):2045. doi: 10.3390/pharmaceutics14102045. PubMed |
| A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins. Chonira V, Kwon YD, Gorman J, Case JB, Ku Z, Simeon R, Casner RG, Harris DR, Olia AS, Stephens T, Shapiro L, Bender MF, Boyd H, Teng IT, Tsybovsky Y, Krammer F, Zhang N, Diamond MS, Kwong PD, An Z, Chen Z. Nat Chem Biol. 2023 Mar;19(3):284-291. doi: 10.1038/s41589-022-01193-2. Epub 2022 Nov 21. PubMed |
| Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. Bednash JS, Johns F, Farkas D, Elhance A, Adair J, Cress K, Yount JS, Kenney AD, Londino JD, Mallampalli RK. Am J Respir Cell Mol Biol. 2023 May;68(5):566-576. doi: 10.1165/rcmb.2022-0331OC. PubMed |
| Immunization of Mice with Virus-Like Vesicles of Kaposi Sarcoma-Associated Herpesvirus Reveals a Role for Antibodies Targeting ORF4 in Activating Complement-Mediated Neutralization. Lam AK, Roshan R, Miley W, Labo N, Zhen J, Kurland AP, Cheng C, Huang H, Teng PL, Harelson C, Gong D, Tam YK, Radu CG, Epeldegui M, Johnson JR, Zhou ZH, Whitby D, Wu TT. J Virol. 2023 Feb 28;97(2):e0160022. doi: 10.1128/jvi.01600-22. Epub 2023 Feb 9. PubMed |
| SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Martinez-Marmol R, Giordano-Santini R, Kaulich E, Cho AN, Przybyla M, Riyadh MA, Robinson E, Chew KY, Amor R, Meunier FA, Balistreri G, Short KR, Ke YD, Ittner LM, Hilliard MA. Sci Adv. 2023 Jun 9;9(23):eadg2248. doi: 10.1126/sciadv.adg2248. Epub 2023 Jun 7. PubMed |
| Whole genome CRISPR screening strategy to identify genes contributing to SARS-CoV-2 spike and VSV-G mediated entry. Hossain MS, Kerkvliet JG, Hoppe AD. J Med Virol. 2023 Sep;95(9):e29087. doi: 10.1002/jmv.29087. PubMed |
| The SARS-CoV-2 spike glycoprotein interacts with MAO-B and impairs mitochondrial energetics. Pileggi CA, Parmar G, Elkhatib H, Stewart CM, Alecu I, Cote M, Bennett SAL, Sandhu JK, Cuperlovic-Culf M, Harper ME. Curr Res Neurobiol. 2023 Oct 6;5:100112. doi: 10.1016/j.crneur.2023.100112. eCollection 2023. PubMed |
| Quantifying Fluorescence Lifetime Responsiveness of Environment-Sensitive Probes for Membrane Fluidity Measurements. Ragaller F, Sjule E, Urem YB, Schlegel J, El R, Urbancic D, Urbancic I, Blom H, Sezgin E. J Phys Chem B. 2024 Mar 7;128(9):2154-2167. doi: 10.1021/acs.jpcb.3c07006. Epub 2024 Feb 28. PubMed |
| Cell-engineered virus-mimetic nanovesicles for vaccination against enveloped viruses. Han C, Kim S, Seo Y, Lim M, Kwon Y, Yi J, Oh SI, Kang M, Jeon SG, Park J. J Extracell Vesicles. 2024 Apr;13(4):e12438. doi: 10.1002/jev2.12438. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.